Suppr超能文献

西洛多辛、坦索罗辛、西洛多辛联合他达拉非以及坦索罗辛联合他达拉非作为输尿管下段结石药物排石疗法的比较研究:一项前瞻性随机试验。

Comparative study between silodosin, tamsulosin, silodosin plus tadalafil, and tamsulosin plus tadalafil as a medical expulsive therapy for lower ureteral stones: a prospective randomized trial.

作者信息

Dogha Mohamed Mahmoud, Sherif Ismail Gamal A, Madney Yasmin M, Harb Hadeer S, Rabea Hoda

机构信息

Department of Urology, Faculty of Medicine, Fayoum University, Faiyum, Egypt.

Department of Clinical Pharmacy, Faculty of Pharmacy, Beni-Suef University, Beni Suef, Egypt.

出版信息

Int Urol Nephrol. 2025 Jun;57(6):1827-1833. doi: 10.1007/s11255-024-04356-3. Epub 2025 Jan 10.

Abstract

PURPOSE

To examine the safety and efficiency of a single-drug therapy with silodosin or tamsulosin versus combined therapy with silodosin plus tadalafil and tamsulosin plus tadalafil as a medical expulsive therapy (MET) for lower ureteral stones.

METHODS

This research was a prospective randomized clinical trial carried out at Fayoum University Hospital, Egypt, over one year. Patients with lower ureteral stones (5-10 mm) were randomly allocated into one of four treatment groups. Group A received silodosin 8 mg per day; Group B received tamsulosin 0.4 mg per day; Group C received silodosin 8 mg plus tadalafil 5 mg daily, and Group D received tamsulosin 0.4 mg plus tadalafil 5 mg daily. Treatment was prescribed for up to 4 weeks. The study outcomes were the stone expulsion rate, stone expulsion time, the amount of analgesics used, the frequency of pain episodes, hospital visits, and any treatment-related adverse effects.

RESULTS

One hundred eighty patients who fulfilled the inclusion criteria completed the study. Group C had a significantly elevated stone expulsion rate (91.1%) compared to Group A (57.8%) and Group B (71.1%) [P = 0.015, P < 0.001, respectively]. Group D had a significantly elevated stone expulsion rate (86.7%) compared to Group B (57.8%) [P = 0.002] and higher than Group A (71.1%). Group C and Group D had significantly less stone expulsion time, analgesic needs, and episodes of renal colic, and fewer hospital visits than Group A and Group B. No significant differences were found in adverse effects like orthostatic hypotension, dizziness, backache, headache, myalgia, and nausea between the patient groups.

CONCLUSION

Combining silodosin with tadalafil and tamsulosin with tadalafil was more efficient as MET for lower ureteric stones than a single treatment with silodosin or tamsulosin.

摘要

目的

探讨使用西洛多辛或坦索罗辛单药治疗与西洛多辛联合他达拉非及坦索罗辛联合他达拉非作为药物排石疗法(MET)治疗输尿管下段结石的安全性和有效性。

方法

本研究是在埃及法尤姆大学医院进行的一项为期一年的前瞻性随机临床试验。将输尿管下段结石(5 - 10毫米)患者随机分为四个治疗组之一。A组每天服用8毫克西洛多辛;B组每天服用0.4毫克坦索罗辛;C组每天服用8毫克西洛多辛加5毫克他达拉非,D组每天服用0.4毫克坦索罗辛加5毫克他达拉非。治疗疗程最长为4周。研究结果包括结石排出率、结石排出时间、使用的镇痛药剂量、疼痛发作频率、就诊次数以及任何与治疗相关的不良反应。

结果

180名符合纳入标准的患者完成了研究。与A组(57.8%)和B组(71.1%)相比,C组的结石排出率显著提高(91.1%)[P分别为0.015和<0.001]。与B组(57.8%)相比,D组的结石排出率显著提高(86.7%)[P = 0.002],且高于A组(71.1%)。与A组和B组相比,C组和D组的结石排出时间、镇痛药需求和肾绞痛发作次数显著减少,就诊次数也更少。各患者组之间在体位性低血压、头晕、背痛、头痛、肌痛和恶心等不良反应方面未发现显著差异。

结论

与单独使用西洛多辛或坦索罗辛治疗相比,西洛多辛联合他达拉非以及坦索罗辛联合他达拉非作为输尿管下段结石的药物排石疗法更有效。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验